MEDICURE INC (MCUJF)

OTC Pharmaceutical Pharmaceutical Preparations SIC: 2834
A+
Pipeline Grade

Drug Pipeline (2 Assets)

DrugPhaseIndications
TIROFIBAN HYDROCHLORIDE
AGGRASTAT 		APPROVED Acute Coronary Syndromes, Coronary Artery Bypass Graft Surgery, Coronary Artery Disease, Coronary Artery Stenosis, de Novo Lesions in Native Coronary Arteries, Diabetes Mellitus, Type 2, Hypertension, Metabolic Syndrome, Myocardial Infarction, Myocardial Ischemia, Myocardial Revascularization, Percutaneous Coronary Intervention, Pyridox(am)Ine 5'-Phosphate Oxidase Deficiency, Renal Insufficiency, Reperfusion Injury, Tardive Dyskinesia, Unstable Angina
PITAVASTATIN MAGNESIUM
ZYPITAMAG 		APPROVED —

Upcoming Catalysts

DateEventDrug
2026-11-01 Phase3 Readout —

Active Clinical Trials (1)

NCT #TitlePhaseStatusEnrollment
NCT04706013 Oral Pyridoxal 5'-Phosphate for the Treatment of Patients With PNPO Deficiency PHASE3 Recruiting 15

Source: ClinicalTrials.gov. Trial status last updated by sponsor — may not reflect current state.

More Analysis

AI Stock Score

SEC EDGAR fundamental analysis with Claude AI & ChatGPT ratings for MCUJF.

SEC EDGAR Filings

All SEC filings for MEDICURE INC on EDGAR.

Full Calendar

View all upcoming FDA catalysts across all biotech companies.